MVP: Advancing Cancer Care Quality Measures

MIPS Value Pathways (MVP): Advancing Cancer Care Quality

The ACC MVP contains multiple quality measures. Click on each quality measure below, which is available in iKM/Practice Insights, for more information.

MIPS #47 Advance Care Planning MIPS #134 Depression Screening MIPS #143 Pain Intensity Quantified MIPS #144 Pain Care Plan MIPS # PIMSH 13 Mutation Testing for Stage IV Lung Cancer Completed Prior to the Start of Targeted Therapy MIPS #453 Percentage of Patients Who Died from Cancer Receiving Systemic Cancer-Directed Therapy in the Last 14 Days of Life MIPS # 457 Percentage of Patients Who Died from Cancer Admitted to Hospice for Less than 3 days MIPS #451 RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy MIPS #450 Appropriate Treatment for Patients with Stage I (T1c) - III HER2 Positive Breast Cancer MIPS # 462 Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy MIPS #PIMSH 17 Oncology: Utilization of Prophylactic GCSF for Cancer Patients Receiving Low-Risk Chemotherapy (Inverse Measure)